Compare Duolingo Inc (DUOL) vs Pfizer Inc (PFE) Price & Performance

Duolingo (DUOL) trades at $150.50, down 0.8% on the day, as the stock consolidates near key resistance at $151. The company demonstrates strong fundamental momentum with revenue reaching $1.04 billion in 2025 and net income surging to $414 million, representing a robust 39.9% margin. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $0.66 exceeding the $0.604 forecast. Technical indicators show a bullish moving average alignment while RSI levels suggest potential near-term consolidation.

Duolingo presents a compelling growth story with accelerating profitability and strong user engagement, though valuation multiples remain elevated. Key risks include increased competition in edtech and insider selling activity. Analyst consensus leans cautious with a $140.63 price target below current levels, suggesting potential near-term headwinds despite the company's operational excellence.

Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.

The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.